The affirmance removes a patent overhang on Sanofi's pneumococcal vaccine business. With the IPR final, Sanofi faces no immediate patent challenge from Pfizer on these claims. Monitor for any potential Supreme Court cert petition, though unlikely given the nonprecedential nature. The ruling is a modest positive for SNY's vaccine segment.
Price Chart
Executive Summary
The Federal Circuit affirmed the PTAB's denial of Pfizer's motion to amend patent claims in three IPR proceedings, ruling that Pfizer's proposed substitute claims for pneumococcal vaccine patent U.S. 9,492,559 would have been obvious. This is a final win for Sanofi, removing a potential patent infringement threat to its pneumococcal vaccine franchise.
Court Ruling Details
Key Facts
- Federal Circuit affirmed PTAB's obviousness finding for Pfizer's proposed substitute claims 48 and 49
- Sanofi (appellee) successfully defended against Pfizer's attempt to amend patent claims covering pneumococcal vaccine compositions
- Ruling is nonprecedential but final, with no further appeal available
- Patent U.S. 9,492,559 covers immunogenic compositions with specific S. pneumoniae serotypes conjugated to CRM197
Financial Impact
No damages awarded; ruling eliminates potential patent infringement liability for Sanofi's pneumococcal vaccines, but financial impact is not quantified in the opinion
Risk Factors
- Pfizer could theoretically seek certiorari, but the nonprecedential disposition and lack of novel legal issues make this unlikely
- Other patent challenges to Sanofi's pneumococcal vaccine portfolio may still exist
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 court opinions from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-3479514c72-SNY |
| COURT-RULING Data (Synthetic) | court-6391b880d2-SNY |
| COURT-RULING Data (Synthetic) | court-6a6fb94ccc-SNY |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | Court Ruling | $44.36 $40.74 | ▼ −8.16% | ▼ −7.97% | $39.92 (−10.01%) |
Aug 17, 2026 6w ago | Court Ruling | $44.41 $42.40 | ▼ −4.53% | ▼ −2.55% | $39.92 (−10.11%) |
Aug 12, 2026 7w ago | Court Ruling | $43.71 $42.72 | ▼ −2.26% | ▼ −0.37% | $39.92 (−8.67%) |
Jul 31, 2026 9w ago | Court Ruling | $43.08 $44.82 | ▲ +4.04% | ▲ +1.05% | $39.92 (−7.34%) |
Jul 30, 2026 9w ago | 6-K | $42.89 $44.84 | ▲ +4.55% | ▲ +0.58% | $39.92 (−6.92%) |
Jul 27, 2026 9w ago | 6-K | $44.00 $45.69 | ▼ −3.84% | ▼ −0.54% | $39.92 (+9.27%) |
Jul 17, 2026 11w ago | 6-K | $44.66 $43.72 | ▼ −2.10% | ▼ −6.55% | $39.92 (−10.61%) |
Jul 7, 2026 12w ago | 6-K | $42.98 $42.95 | ▼ −0.07% | ▼ −1.40% | $39.92 (−7.12%) |
Apr 13, 2026 24w ago | Court Ruling | $44.49 $42.50 | ▼ −4.48% | ▼ −12.20% | $39.92 (−10.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access